Skip to main content
Journal cover image

In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors.

Publication ,  Journal Article
Eubanks, AL; Perkins, MM; Sylvester, K; Ganley, JG; Posfai, D; Sanschargrin, PC; Hong, J; Sliz, P; Derbyshire, ER
Published in: ChemMedChem
December 2018

An in silico screen of 350 000 commercially available compounds was conducted with an unbiased approach to identify potential malaria inhibitors that bind to the Plasmodium falciparum protein kinase 5 (PfPK5) ATP-binding site. PfPK5 is a cyclin-dependent kinase-like protein with high sequence similarity to human cyclin-dependent kinase 2 (HsCDK2), but its precise role in cell-cycle regulation remains unclear. After two-dimensional fingerprinting of the top scoring compounds, 182 candidates were prioritized for biochemical testing based on their structural diversity. Evaluation of these compounds demonstrated that 135 bound to PfPK5 to a similar degree or better than known PfPK5 inhibitors, confirming that the library was enriched with PfPK5-binding compounds. A previously reported triazolodiamine HsCDK2 inhibitor and the screening hit 4-methylumbelliferone were each selected for an analogue study. The results of this study highlight the difficult balance between optimization of PfPK5 affinity and binding selectivity for PfPK5 over its closest human homologue HsCDK2. Our approach enabled the discovery of several new PfPK5-binding compounds from a modest screening campaign and revealed the first scaffold to have improved PfPK5/HsCDK2 selectivity. These steps are critical for the development of PfPK5-targeting probes for functional studies and antimalarials with decreased risks of host toxicity.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

ChemMedChem

DOI

EISSN

1860-7187

ISSN

1860-7179

Publication Date

December 2018

Volume

13

Issue

23

Start / End Page

2479 / 2483

Related Subject Headings

  • Structure-Activity Relationship
  • Protozoan Proteins
  • Protein Kinase Inhibitors
  • Plasmodium falciparum
  • Medicinal & Biomolecular Chemistry
  • Malaria, Falciparum
  • Humans
  • Hep G2 Cells
  • Drug Discovery
  • Cyclins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Eubanks, A. L., Perkins, M. M., Sylvester, K., Ganley, J. G., Posfai, D., Sanschargrin, P. C., … Derbyshire, E. R. (2018). In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors. ChemMedChem, 13(23), 2479–2483. https://doi.org/10.1002/cmdc.201800625
Eubanks, Amber L., Marisha M. Perkins, Kayla Sylvester, Jack G. Ganley, Dora Posfai, Paul C. Sanschargrin, Jiyong Hong, Piotr Sliz, and Emily R. Derbyshire. “In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors.ChemMedChem 13, no. 23 (December 2018): 2479–83. https://doi.org/10.1002/cmdc.201800625.
Eubanks AL, Perkins MM, Sylvester K, Ganley JG, Posfai D, Sanschargrin PC, et al. In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors. ChemMedChem. 2018 Dec;13(23):2479–83.
Eubanks, Amber L., et al. “In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors.ChemMedChem, vol. 13, no. 23, Dec. 2018, pp. 2479–83. Epmc, doi:10.1002/cmdc.201800625.
Eubanks AL, Perkins MM, Sylvester K, Ganley JG, Posfai D, Sanschargrin PC, Hong J, Sliz P, Derbyshire ER. In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors. ChemMedChem. 2018 Dec;13(23):2479–2483.
Journal cover image

Published In

ChemMedChem

DOI

EISSN

1860-7187

ISSN

1860-7179

Publication Date

December 2018

Volume

13

Issue

23

Start / End Page

2479 / 2483

Related Subject Headings

  • Structure-Activity Relationship
  • Protozoan Proteins
  • Protein Kinase Inhibitors
  • Plasmodium falciparum
  • Medicinal & Biomolecular Chemistry
  • Malaria, Falciparum
  • Humans
  • Hep G2 Cells
  • Drug Discovery
  • Cyclins